The Motley Fool

Why Nordion Shares Soared Today

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.

What: Shares of Nordion Inc (TSX: NDN) popped 11% today after sterilization services provider Sterigenics agreed to acquire the Canadian medical isotopes supplier for U.S. $727 million.

So what: The all-cash deal values Nordion at U.S. $11.75 per share and represents a 13% premium to its closing price on Friday. Nordion is one of the world’s biggest producers of molybdenum-99, an isotope used in medical imaging, so Sterigenics is naturally making the move to expand its presence in the growing field of gamma sterilization.

Now what: The transaction isn’t subject to any financial conditions and is expected to close in the second half of this year. “This transaction delivers value to our shareholders and is a good strategic fit for Nordion”, said Nordion CEO Steve West. “We believe this partnership is beneficial to Nordion’s employees and our customers, as Nordion and Sterigenics combine their global expertise, industry knowledge and the same focus on high quality standards and values. This transaction also marks the successful completion of Nordion’s strategic review.”

But while Nordion shareholders can certainly wait for the full price of $11.75, rolling at least some of today’s profit into more diversified plays like Balchem and Covidien seems prudent.

The 10 Best Stocks to Buy This Month

Renowned Canadian investor Iain Butler just named 10 stocks for Canadians to buy TODAY. So if you’re tired of reading about other people getting rich in the stock market, this might be a good day for you. Because Motley Fool Canada is offering a full 65% off the list price of their top stock-picking service, plus a complete membership fee back guarantee on what you pay for the service. Simply click here to discover how you can take advantage of this.

Click Here to Learn More Today!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned.

I consent to receiving information from The Motley Fool via email, direct mail, and occasional special offer phone calls. I understand I can unsubscribe from these updates at any time. Please read the Privacy Statement and Terms of Service for more information.